Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Rating of “Moderate Buy” from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been given an average recommendation of “Moderate Buy” by the nineteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $246.0588.

A number of brokerages recently issued reports on JAZZ. Barclays upped their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Leerink Partners boosted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Truist Financial set a $256.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th.

Insider Activity

In other news, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the transaction, the director directly owned 9,680 shares of the company’s stock, valued at $2,231,724. This represents a 10.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,098 shares of company stock worth $2,832,086. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Hilltop National Bank bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $36,000. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $38,000. Danske Bank A S bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $40,000. Geneos Wealth Management Inc. boosted its stake in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ:JAZZ opened at $224.66 on Friday. The stock has a market capitalization of $14.11 billion, a PE ratio of -11,227.39, a P/E/G ratio of 0.20 and a beta of 0.32. Jazz Pharmaceuticals has a 1 year low of $105.00 and a 1 year high of $243.32. The firm has a fifty day moving average price of $220.76 and a 200 day moving average price of $190.29. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Analysts expect that Jazz Pharmaceuticals will post 22.09 EPS for the current fiscal year.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz Pharmaceuticals announced a collaboration with AbCellera to discover and develop next-generation T-cell-engaging multispecific antibodies for GI cancers and other solid tumors, a deal that could expand JAZZ’s oncology pipeline and create future licensing or milestone revenue. Article Title
• Positive Sentiment: Multiple reports highlighted the size of the AbCellera agreement, with potential value cited in the hundreds of millions of dollars per program, reinforcing investor interest in Jazz’s ability to use external partnerships to deepen its cancer franchise. Article Title
• Neutral Sentiment: Jazz also shared late-breaking data on Xywav at SLEEP 2026, underscoring continued clinical and commercial support for its neuroscience business, though this update appears less immediate than the AbCellera news. Article Title
• Negative Sentiment: Investors may also note that Director Mark Douglas Smith sold 1,157 shares in a pre-arranged Rule 10b5-1 transaction, which can create a modest negative sentiment signal even though the sale was planned. Article Title

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.